1 / 22

The Performance of the Regional Laboratory Network Nairobi, 2-3 June 2015

AFR Measles-Rubella TAG Meeting. The Performance of the Regional Laboratory Network Nairobi, 2-3 June 2015. Outline. Distribution of measles laboratories in AFR Region Performance indicators Measles g enotypes Main Challenges Way forward Question for TAG members.

esterprice
Download Presentation

The Performance of the Regional Laboratory Network Nairobi, 2-3 June 2015

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. AFR Measles-Rubella TAG Meeting The Performance of the Regional Laboratory Network Nairobi, 2-3 June 2015

  2. Outline • Distribution of measleslaboratories in AFR Region • Performance indicators • Measlesgenotypes • Main Challenges • Wayforward • Question for TAG members

  3. Distribution of Measles Rubella Lab. • N=47 labs • One lab/country except NIE (4) & ETH (3) • No lab: EQG, STP, CAV, SEY, MAS • Funding: MR initiative National Lab Sub National Lab Regional Ref. Lab

  4. Distribution of Measles Rubella Lab. Network (cn’t) • Coordination at IST level • 1 labperson: IST ESA • 1 labperson: ISTs CA/WA • Diagnostic capacities • Serology: all labs • Virus isolation/PCR: selectedlabs • Sequencing: 3 RRLs

  5. Standardization: equipments (purchased by WHO), technique, kits, testing algorithm, lab database External quality control system in place Regular trainings (bench work & data management) organized Monitoring of performance indicators Accreditation review & lab director meeting WHO support: kits, basic supplies, funds for operationnal cost Main Lab. Network Activities

  6. Main Lab. Performance Indicators

  7. Timeliness & Completeness in Sharing Database Few labs have met the expected target (>=80%) due to internet connexion challenges, conflicting priority activities, staffing problems

  8. Workload at Laboratory 2014: Drop in number of specimens received at NLs in WA & in number of specimens received at IPCIV RRL (Impact of EVD outbreak) Increase in number of specimens received at NICD RRL (re establishment of testing)

  9. Workload at Laboratory (cn’t) • Few shipmentsperformed by NLs in 2014 vs 2013 • No shipmentperformed by somelabs • Refusalfrom DHL carrier to organizeshipment of bloodspecimen due to on going EVD outbreak in WA

  10. Quality of Specimens Specimens received in good condition in most of the case. 90% minimum target met except for specimen received at NICD lab in 2014)

  11. Suspected case of measles Blood specimen IgM(+) IgM(-) IgM(-/+) Lab. Testing Algorithm Rubella IgM (-) Rubella IgM (+) Rubella IgM (-/+) Measles IgM Rubella IgM Repeat Measles IgM Measles IgM (+) Measles IgM (-) Measles IgM (+/-)

  12. Lab. Testing Algorithm (cn’t) Some labs do not strictly follow algorithm & run simultaneous measles & rubella IgM test to save times

  13. Timeliness in sending out IgM results to EPI/surveillance WA below the 80% expected target in 2013 & 2014 due to shortage of kits (NIE impact)- Long term shortage of kits in 2014 (funding issues) affected most labs

  14. Timeliness in sending out IgM results to EPI/surveillance

  15. Timeliness in sending back IgM Results to NLs • Expectedtargetnot met • By IPCIV RRL in 2013 & 2014 • By NICD RRL in 2014 • IPCIV= RRL for 27 NLs. High number of specimensusuallyreceived (incl. from Nigeria) • Shortage of kits has affectedthisindicator for IPCIV

  16. Supply of Kits • High number of kits purchased in 2014 (twice more) than 20013 • Increasingneedsfromlabs. Reason: outbreak ??? • Unit price for Siemens IgM kit: Measle & rubella (295 Euros each), Supplementary (39 Euros) • Total cost (excluding transport) • 2013: 172 264 Euros • 2014: 337 592 Euros

  17. Proficiency Test & Accreditation status Excellent performance obtained for annual Proficiency Test except 1 lab (not accredited) - Sub optimal documentation & implementation of internal quality control procedures (provisionally accredited),

  18. Measles Genotype Identified: 2005-2014 • Identifiedfromspecimencollectedfromoutbreak & QC • Sequencingperformedlab: NICD,UVRI & CDC • IPCIV: sequencingstarted in 2015 • B3 largelycirculating (In 2014 identified in ZIM,NIE & TOG) B3 B2 D4 D2 D10

  19. Main Challenges • Suboptimal weekly reporting timeliness/completeness • Internet connectivity problems • Competing laboratory activities • High staff turn over in some labs (ETH, MAL, South Sudan) • Inconsistency in management of lab reagent • Stock outs ok kit due to outbreaks • Inaccuracy in estimating the needs & supply of kits with short expiring date • Insufficient/inadequate coordination between lab & surveillance • Continuous collection of blood specimen during measles outbreaks • Missed opportunity to collect specimen for virus isolation/genotyping

  20. Main Challenges (cn’t) • Limited funding to cover lab activities (heavily dependant on WHO) • To purchase kits & sequencing reagents/supplies • To organize trainings • Effect of EVD outbreak • Shipment of QC specimen stopped in several countries, • 2014 lab director meeting cancelled

  21. Way Forward • Integration of additional measles lab: SEY, Mauritius (countries on elimination mode) • Full implementation of sequencing activities at IPCIV RRL • Strengthen collaboration between lab & surveillance • Secure alternative carriers to transport specimens for QC • Reconvene annual lab director meeting • Advocate for additional funding for the lab network - Explore Nigeria willingness to purchase kits

  22. Question For MR TAG Members How can we advocate /mobilize more funds to cover measles laboratory network needs???

More Related